Phospho-indoles as HIV inhibitors

Details Phospho-indoles as HIV inhibitors Phospho-indoles as HIV inhibitors

2008-11-21

2011-10-25

Shiao, Rei-tsang (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S111000, C548S492000

Reexamination Certificate

active

08044091

ABSTRACT:
3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

REFERENCES:
patent: 4866084 (1989-09-01), Gunasekera et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5489685 (1996-02-01), Houpis et al.
patent: 5527819 (1996-06-01), Williams et al.
patent: 5565446 (1996-10-01), Boschelli et al.
patent: 5703069 (1997-12-01), Connor et al.
patent: 5830894 (1998-11-01), Pevear et al.
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 5929114 (1999-07-01), Domagala et al.
patent: 5935982 (1999-08-01), Dykstra et al.
patent: 5945440 (1999-08-01), Kleinschroth et al.
patent: 5981525 (1999-11-01), Farina et al.
patent: 6017903 (2000-01-01), Slusher et al.
patent: 6025345 (2000-02-01), Jackson et al.
patent: 6025390 (2000-02-01), Farina et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6710068 (2004-03-01), La Colla et al.
patent: 6716605 (2004-04-01), Fujishita et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 6900206 (2005-05-01), Kadow et al.
patent: 7534809 (2009-05-01), Storer et al.
patent: 2002/0019434 (2002-02-01), Fujishita et al.
patent: 2003/0096825 (2003-05-01), Wang et al.
patent: 2003/0236277 (2003-12-01), Kadow et al.
patent: 2004/0006090 (2004-01-01), Kadow et al.
patent: 2004/0063746 (2004-04-01), Regueiro-Ren et al.
patent: 2006/0074054 (2006-04-01), Storer et al.
patent: 2008/0213217 (2008-09-01), Storer et al.
patent: 1 961 757 (2008-08-01), None
patent: 1 799 696 (2008-11-01), None
patent: WO 94/19321 (1994-09-01), None
patent: WO 96/29077 (1996-09-01), None
patent: WO 97/48399 (1997-12-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 97/48409 (1997-12-01), None
patent: WO 98/13046 (1998-04-01), None
patent: WO 98/38332 (1998-09-01), None
patent: WO 98/53812 (1998-12-01), None
patent: WO 99/52915 (1999-10-01), None
patent: WO 01/02388 (2001-01-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 03/090691 (2003-11-01), None
patent: WO 03/091264 (2003-11-01), None
patent: WO 2004/014364 (2004-02-01), None
patent: WO 2006/054182 (2007-03-01), None
EPO, Communication pursuant to Article 96(2) EPC, dated Nov. 16, 2007 for European patent application No. 05850774.0.
ISA/EP, International Search Report, dated Apr. 1, 2008 for International Application No. PCT/US2007/020900.
ISA/EP, PCT International Preliminary Report on Patentability, dated Mar. 31, 2009 for International Application No. PCT/US2007/020900.
EPO, Communication under Rule 71(3) EPC of intent to grant an European patent, dated Feb. 2, 2010, for European Patent Application No. 08075531.7 (division of European Application Patent No. 05850774.0).
EPO, Communication pursuant to Article 94(3) EPC, dated Feb. 11, 2010, for European Patent Application No. 07838974.9.
USPTO, non-final Office Action, mailed Dec. 11, 2009, for U.S. Appl. No. 11/906,095.
USPTO, Final Office Action, mailed Jul. 22, 2010, for U.S. Appl. No. 11/906,095.
ISA/EP International Search Report dated Nov. 23, 2006, for International Application No. PCT/IB2005/004063, filed Sep. 16, 2005.
ISA/EP Written Opinion of the International Searching Authority dated Nov. 23, 2006, for International Application No. PCT/IB2005/004063, filed Sep. 16, 2005.
EPO Communication pursuant to Article 96(2) EPC dated Jul. 6, 2007, for European Patent Application No. 05 850 774.0-2117, with attached Beilstein Crossfire Search per Section V. 2.5 of the Written Opinion.
European Search Report dated Jul. 25, 2008, for European Application No. 08075531.7 (division of European Application No. 05850774.0), filed Sep. 16, 2005.
Singapore Written Opinion dated Jul. 7, 2008, referencing Australian Patent Office Written Opinion dated Jun. 27, 2008, for Singapore Patent Application No. 200702002-7 (based on International Application No. PCT/IB2005/004063), filed Sep. 16, 2005.
Abdou et al., 2004, “Phosphono-Substituted Isoindolines and Indoles from 2,3- and 2,4- Benzoxazin-1-1 ones,” Heteroatom Chemistry, vol. 15:77-84.
Abousaoude and Collignon, 1985, “Dialkyl Formyl-1 Methylphosphonates α-Fonctionnels-II,” Tetrahedron, vol. 41(2):427-433.
Alexandre et al., 2007, “Synthesis and Antiviral Activity of Phospho-Indoles as Novel NNRTI with Potent Anti-HIV Activity and Enhanced Barrier to Resistance,” Poster presented at ASMC07, St. Petersburg, Russia (Aug. 28-31, 2007).
Alexandre et al., 2007, “IDX 12899; A Novel and Highly Potent anti-HIV Non-Nucleosidic-Reverse-Transcriptase-Inhibitor with Enhanced Barrier to Resistance Profile,” Poster 21 presented at 14thSCI-RSC Medicinal Chemistry Symposium, Cambridge, UK (Sep. 23-26, 2007).
Aoyagi et al., 1974, “Studies on Chromogenic and Fluorogenic Substrates for Detection of Enzymatic Activities,” J. Fac. Eng. Chiba Univ., 26(49):185-191.
Artico et al., 1996, “2-Sulfonyl-4-Chloroanilino Moiety: A Potent Pharmacophore for the Anti-Human Immunodeficiency Virus Type 1 Activity of Pyrrolyl Aryl Sulfones,” J. Med. Che., 39:522-530.
Artico et al., 1997, “1-Arylsulfony1-3-(α-hydroxybenzy1)-1H-Pyrroles, a Novel Class of Anti-HIV-1 Reverse Transcriptase Inhibitors,” Bioorganic & Med. Chem. Letters 7:1931-1936.
Artico et al., 2000, “Strucure-Based Design, Synthesis, and Biological Evaluation of Novel Pyrrolyl Aryl Sulfones: HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors Active at Nanomolar Concentrations,” J. Med. Chem., 43:1886-1891.
Asadov et al., 2003, “Synthesis of 3-Phosphorylated Indoles from α-Chloro Aldehydes,” Chemistry of Heterocyclic Compounds, vol. 39(11):1521-1522.
Baba et al., 1992, “Highly Potent and Selective Inhibition of HIV-1 Replication by 6-Phenylthiouracil Derivatives,” Antiviral Res., 17:245-264.
Balzarini et al., 1992, “2′5′-Bis-O-(tert-Butyldimethylsilyl)-3′-Spiro5″-(4″-Amino-1″,2″-Oxathiole-2″,2″-Dioxide) Pyrimidine (TSAO) Nucleoside Analogues: Highly Selective Inhibitors of Human Immunodeficiency Virus Type 1 that are Targeted at the Viral Reverse Transcriptase,” PNAS, 89:4392-4396.
Beilstein Registry No. 284968, Chemical Name “di-indol-3-yl-phosphinic acid,” Beilstein Entry Date: Jun. 27, 1988.
Bell et al., 1995, “Phenethylthiazolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure—Activity Relationship Studies of PETT Analogs,” J. Med. Chem., 38:4929-4936.
Benincori et al., 2000, “3,3″-Bis(diphenylphosphino)-1,1″-disubstituted-2-2″-biindoles: Easily Accessible, Electron-Rich, Chiral Diphosphine Ligands for Homogeneous Enantioselective Hydrogenation of Oxoesters,” J. Org. Chem., vol. 65:8340-8347.
Blechert, 1985, “Hetero-Cope-Rearrangements. Regio-Controlled Synthesis of Indoles,” Helvetica Chimica Acta., vol. 68:1835-1843.
Cantrell et al., 1996, “Phenethylthiazolylthiourea (PETT) Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure—Activity Relationship Studies of PETT Analogs,” J. Med. Chem., 39:4261-4274.
Chen et al., 1997, “Synthesis of Indoles via a Palladium-Catalyzed Annulation between Iodoanilines and Ketones,” J. Org. Chem., 62(9):2676-2677.
Danel et al., 1996, “Synthesis of Potent Anti-HIV-1 Activity of Novel 6-Benzyluracil Analogues of 1-[(2- Hydroxyethoxy)methyl]-6-(phenylthio)thymine,” J. Med. Chem., 39:2427-2431.
Danel et al., 1997, “Anti-HIV Active Naphthyl Analogues of HEPT and DABO,” Acta Chemica Scandinavica, 51:426-430.
Declercq, 1992, “HIV Inhibitors Targeted at the

Affiliated with

Also associated with

Rating

Phospho-indoles as HIV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phospho-indoles as HIV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phospho-indoles as HIV inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4253050